Report reveals murky picture of clinical trial diversity gains

Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

By Alexandra Pecci • Jan. 24, 2023

Already on a roll in oncology, Astellas hunts for big wins in other areas

With two potential first-in-class drug launches on the horizon, and a budding gene therapy business, Astellas believes this year could be a major inflection point. 

By Karissa Waddick • Jan. 23, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

A Moderna tie-up ushers in new era for CytomX

The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

By Michael Gibney • Jan. 18, 2023

Woman of the Week: Genetika+’s Talia Cohen Solal

The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

By Taren Grom • Jan. 18, 2023

Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

Space — the next frontier in drug development

Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

By Kelly Bilodeau • Jan. 12, 2023

Woman of the Week: Form Bio’s Claire Aldridge

The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

By Taren Grom • Jan. 11, 2023

Galecto has identified a master switch to reduce fibroid formation

With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

By Taren Grom • Jan. 11, 2023

Chinook Therapeutics nears the finish line in kidney disease

A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

By Michael Gibney • Jan. 10, 2023

The kindred nature of martial arts and drug development

How the IRLAB Therapeutics CEO is guiding the company in its development of potentially groundbreaking Parkinson’s disease treatments.

By Alexandra Pecci • Jan. 9, 2023

Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

By Taren Grom • Jan. 9, 2023

Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

By Michael Gibney • Jan. 5, 2023

Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

Woman of the Week: Cambrian BioPharma’s Juliette Han

The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

By Taren Grom • Jan. 4, 2023

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

By Alexandra Pecci • Jan. 3, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

From chemistry to canvas: What the pharma world can learn from art

Art and science are often viewed as diametric opposites, but these industry insiders say their passion for painting blends into their pharma work. 

By Karissa Waddick • Dec. 22, 2022

Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease

New Alzheimer's drugs are poised to change the market — and in preclinical arenas, researchers are learning more and more about the disease.

By Michael Gibney • Dec. 22, 2022

To drive trial diversity, one company is bringing them to the patient

For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

By Karissa Waddick • Dec. 21, 2022

With mpox cases mysteriously dwindling, scientists search for answers

Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

By Kelly Bilodeau • Dec. 19, 2022

Blood cancer cures aren’t here yet — but incremental combinations bring the field closer

A series of small successes showed promise for the future of blood cancer treatments, particularly in the arena of drug combinations.

By Michael Gibney • Dec. 19, 2022

How one of the world’s most prolific inventors is guiding a plan to tackle all disease

Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.

By Alexandra Pecci • Dec. 15, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

At the heart of hematology breakthroughs, a community of researchers and patients comes together

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

By Michael Gibney • Dec. 13, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022